Clinical Trial Detail

NCT ID NCT02438722
Title S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Southwest Oncology Group
Indications

lung non-small cell carcinoma

Therapies

Afatinib

Afatinib + Cetuximab

Age Groups: child senior adult

No variant requirements are available.